Careers  |  Sign In  |  Register

New Ebola Vaccine On The Verge of Human Trials

An experimental vaccine developed by Canadian scientists at NewLink Genetics Corporation is on the verge of launching its first human clinical trial, according to a report by Reuters. The new drug uses the pathogen vesicular stomatitis virus,where one virus gene is replaced by an Ebola gene, which then produces a harmless protein. Once the altered virus is injected, the immune system should recognize the Ebola protein as foreign and then produce antibodies that destroy the harmful virus. Only one other Ebola medication by Tekmira has reached human trials, though others including the NewLink vaccine and a drug from GlaxoSmithKline are not far behind.

Read the article published by Reuters.